CZ2002561A3 - Fosfolipidový gel - Google Patents

Fosfolipidový gel Download PDF

Info

Publication number: CZ2002561A3
Authority: CZ; Czechia
Prior art keywords: phospholipid; weight; gel; gel according; alcohol
Prior art date: 1999-08-25

Application number

CZ2002561A

Other languages

Czech (cs)

English (en)

Inventor

Bernd Ibscher

Ruland Fridrich

Original Assignee

Merckle Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-25

Filing date

2000-08-16

Publication date

2002-07-17

2000-08-16 Application filed by Merckle Gmbh filed Critical Merckle Gmbh

2002-07-17 Publication of CZ2002561A3 publication Critical patent/CZ2002561A3/cs

Links

150000003904 phospholipids Chemical class 0.000 title claims description 100
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 21
235000000346 sugar Nutrition 0.000 claims abstract description 21
239000002537 cosmetic Substances 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
239000000203 mixture Substances 0.000 claims description 41
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
239000000872 buffer Substances 0.000 claims description 20
150000001875 compounds Chemical class 0.000 claims description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 17
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 15
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical group OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 claims description 15
239000000600 sorbitol Substances 0.000 claims description 15
150000001298 alcohols Chemical class 0.000 claims description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 12
229960004150 aciclovir Drugs 0.000 claims description 10
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 10
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 9
239000000654 additive Substances 0.000 claims description 7
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 6
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 6
229960000890 hydrocortisone Drugs 0.000 claims description 6
102000055006 Calcitonin Human genes 0.000 claims description 5
108060001064 Calcitonin Proteins 0.000 claims description 5
230000003139 buffering effect Effects 0.000 claims description 5
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 5
229960004015 calcitonin Drugs 0.000 claims description 5
229920000669 heparin Polymers 0.000 claims description 5
-1 virostatics Substances 0.000 claims description 5
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims description 4
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
229960001259 diclofenac Drugs 0.000 claims description 4
239000008103 glucose Substances 0.000 claims description 4
229960002897 heparin Drugs 0.000 claims description 4
229940088597 hormone Drugs 0.000 claims description 4
239000005556 hormone Substances 0.000 claims description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
102000039446 nucleic acids Human genes 0.000 claims description 4
108020004707 nucleic acids Proteins 0.000 claims description 4
150000007523 nucleic acids Chemical class 0.000 claims description 4
239000008363 phosphate buffer Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 4
239000005720 sucrose Substances 0.000 claims description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
239000005715 Fructose Substances 0.000 claims description 3
229930091371 Fructose Natural products 0.000 claims description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
229930195725 Mannitol Natural products 0.000 claims description 3
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
239000012298 atmosphere Substances 0.000 claims description 3
239000007853 buffer solution Substances 0.000 claims description 3
239000003246 corticosteroid Substances 0.000 claims description 3
229960001334 corticosteroids Drugs 0.000 claims description 3
239000003349 gelling agent Substances 0.000 claims description 3
239000011261 inert gas Substances 0.000 claims description 3
239000000594 mannitol Substances 0.000 claims description 3
235000010355 mannitol Nutrition 0.000 claims description 3
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
230000001790 virustatic effect Effects 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
239000000811 xylitol Substances 0.000 claims description 3
229960002675 xylitol Drugs 0.000 claims description 3
235000010447 xylitol Nutrition 0.000 claims description 3
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
229960000833 xylometazoline Drugs 0.000 claims description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 claims description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
108010036949 Cyclosporine Proteins 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
239000007995 HEPES buffer Substances 0.000 claims description 2
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
239000007993 MOPS buffer Substances 0.000 claims description 2
239000000150 Sympathomimetic Substances 0.000 claims description 2
239000007983 Tris buffer Substances 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
230000002682 anti-psoriatic effect Effects 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
229940121375 antifungal agent Drugs 0.000 claims description 2
229940030999 antipsoriatics Drugs 0.000 claims description 2
229960001265 ciclosporin Drugs 0.000 claims description 2
229930182912 cyclosporin Natural products 0.000 claims description 2
229960000520 diphenhydramine Drugs 0.000 claims description 2
239000003995 emulsifying agent Substances 0.000 claims description 2
229960000905 indomethacin Drugs 0.000 claims description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
229960000367 inositol Drugs 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
239000003589 local anesthetic agent Substances 0.000 claims description 2
229960005015 local anesthetics Drugs 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
239000000845 maltitol Substances 0.000 claims description 2
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
235000010449 maltitol Nutrition 0.000 claims description 2
229940035436 maltitol Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000007923 nasal drop Substances 0.000 claims description 2
229940100662 nasal drops Drugs 0.000 claims description 2
229940100652 nasal gel Drugs 0.000 claims description 2
229920001542 oligosaccharide Polymers 0.000 claims description 2
150000002482 oligosaccharides Chemical class 0.000 claims description 2
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 2
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
229940064707 sympathomimetics Drugs 0.000 claims description 2
239000002562 thickening agent Substances 0.000 claims description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
229940044950 vaginal gel Drugs 0.000 claims description 2
239000000029 vaginal gel Substances 0.000 claims description 2
229930105110 Cyclosporin A Natural products 0.000 claims 1
229960002737 fructose Drugs 0.000 claims 1
229960001031 glucose Drugs 0.000 claims 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
229960001855 mannitol Drugs 0.000 claims 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
229960002920 sorbitol Drugs 0.000 claims 1
229960004793 sucrose Drugs 0.000 claims 1
230000001975 sympathomimetic effect Effects 0.000 claims 1
229940074410 trehalose Drugs 0.000 claims 1
108010064062 phospholipin Proteins 0.000 abstract 1
239000000499 gel Substances 0.000 description 132
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
239000011780 sodium chloride Substances 0.000 description 18
150000003839 salts Chemical class 0.000 description 14
229940079593 drug Drugs 0.000 description 13
239000003814 drug Substances 0.000 description 13
235000013772 propylene glycol Nutrition 0.000 description 13
238000005259 measurement Methods 0.000 description 12
238000003860 storage Methods 0.000 description 12
239000000126 substance Substances 0.000 description 9
239000003792 electrolyte Substances 0.000 description 8
150000005846 sugar alcohols Chemical class 0.000 description 8
239000000243 solution Substances 0.000 description 7
230000000694 effects Effects 0.000 description 6
210000004400 mucous membrane Anatomy 0.000 description 6
230000010355 oscillation Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
150000008163 sugars Chemical class 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
229960000525 diphenhydramine hydrochloride Drugs 0.000 description 4
210000000245 forearm Anatomy 0.000 description 4
238000000034 method Methods 0.000 description 4
210000002850 nasal mucosa Anatomy 0.000 description 4
210000001331 nose Anatomy 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
230000003534 oscillatory effect Effects 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
238000005316 response function Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000007704 transition Effects 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
206010002153 Anal fissure Diseases 0.000 description 1
208000016583 Anus disease Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004821 Contact adhesive Substances 0.000 description 1
102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000009531 Fissure in Ano Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
206010050637 Skin tightness Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229940061720 alpha hydroxy acid Drugs 0.000 description 1
150000001280 alpha hydroxy acids Chemical class 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002781 deodorant agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000037336 dry skin Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001879 gelation Methods 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229960001008 heparin sodium Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
239000003607 modifier Substances 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000002304 perfume Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
238000013439 planning Methods 0.000 description 1
229920000166 polytrimethylene carbonate Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
235000019605 sweet taste sensations Nutrition 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/0052—Preparation of gels
- B01J13/0065—Preparation of gels containing an organic phase

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Birds (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biophysics (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CZ2002561A 1999-08-25 2000-08-16 Fosfolipidový gel CZ2002561A3 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19940227A DE19940227A1 (de)	1999-08-25	1999-08-25	Phospholipidgel

Publications (1)

Publication Number	Publication Date
CZ2002561A3 true CZ2002561A3 (cs)	2002-07-17

Family

ID=7919498

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ2002561A CZ2002561A3 (cs)	1999-08-25	2000-08-16	Fosfolipidový gel

Country Status (13)

Country	Link
EP (1)	EP1206245A2 (de)
JP (1)	JP2003507408A (de)
AU (1)	AU776766B2 (de)
CA (1)	CA2381571A1 (de)
CZ (1)	CZ2002561A3 (de)
DE (1)	DE19940227A1 (de)
HU (1)	HUP0203097A3 (de)
NO (1)	NO20020768L (de)
PL (1)	PL353215A1 (de)
RU (1)	RU2261088C2 (de)
SK (1)	SK2442002A3 (de)
WO (1)	WO2001013887A2 (de)
ZA (1)	ZA200201506B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002062316A1 (de) *	2001-02-08	2002-08-15	Vectron Therapeutics Ag	Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung
CN1335182A (zh) *	2001-08-08	2002-02-13	华中科技大学	胰岛素口腔喷剂及其制备工艺
DE10255285A1 (de) *	2002-11-26	2004-06-03	Mcs Micro Carrier Systems Gmbh	Selbst formende Phospholipid-Gele
DE10255195A1 (de) *	2002-11-27	2004-06-09	Lipoid Gmbh	Micellare wasserlösliche Konzentrate
ATE385779T1 (de) *	2002-12-20	2008-03-15	Idexx Lab Inc	Dicolfenac-haltige liposomale schmerzstillende formulierung und ihre verwendung zur behandlung von pferden
US7858115B2 (en)	2004-06-24	2010-12-28	Idexx Laboratories	Phospholipid gel compositions for drug delivery and methods of treating conditions using same
FI20065222A7 (fi) *	2006-04-05	2007-10-06	Finnfeeds Finland Oy	Inositolin käyttö
RU2309738C1 (ru) *	2006-08-28	2007-11-10	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Фармацевтический состав с противовоспалительным и обезболивающим действием и способ его получения
ITMI20081862A1 (it) *	2008-10-21	2010-04-22	Funziona Srl	Composizione ad uso topico per il trattamento delle adiposita' localizzate e dei relativi inestetismi
EP2355803A4 (de) *	2008-11-14	2012-04-25	Archer Daniels Midland Co	Organogel-zusammensetzungen und herstellungsverfahren
EP2210589B1 (de) *	2009-01-22	2015-05-06	Ludwig-Maximilians-Universität München	Vesikuläre Phospholipid-Gele mit proteinösen Substanzen
BE1018506A3 (nl) *	2009-02-26	2011-02-01	Bogaert Gina Van	Samenstelling van een hydrocortisone, zijn derivaten, metabolieten, prodrugs of mengsels daarvan houdende liposomale gel en het gebruik ervan.
SG185499A1 (en) *	2010-05-14	2012-12-28	Archer Daniels Midland Co	Food compositions comprising organogels
JP2017214299A (ja) *	2016-05-30	2017-12-07	ライオン株式会社	半固形製剤及びその製造方法
CN110891610B (zh)	2017-03-23	2024-03-01	脂类系统股份公司	亲水性化合物在单层脂质体中的高效包封

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0753661B2 (ja) *	1984-03-08	1995-06-07	フアレスフアーマスーチカルリサーチエヌブイ	プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
JP2501336B2 (ja) *	1987-07-02	1996-05-29	第一製薬株式会社	安定なリポソ−ム製剤
IL94103A0 (en) *	1989-04-25	1991-01-31	Nattermann A & Cie	Water-containing formulations with phospholipids,their preparation and application
US5820848A (en) *	1990-01-12	1998-10-13	The Liposome Company, Inc.	Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent
DE4003783C2 (de) *	1990-02-08	1999-03-25	Nattermann A & Cie	Phospholipidhaltiges Gel, Verfahren zu dessen Herstellung und Verwendung
DE4021082C2 (de) *	1990-07-03	1995-08-17	Hans Dr Lautenschlaeger	Hautbehandlungsmittel mit hohen Lipidgehalten unter Verwendung eines Bilayer enthaltenden Systems, Salzen organischer Säuren, Alkohol und Stabilisator
FR2720937B1 (fr) *	1994-06-08	1997-03-28	Oreal	Composition cosmétique ou dermatologique sous forme de dispersion, aqueuse et stable, de particules de gel cubique à base de phytantriol et contenant un agent tensioactif à chaîne grasse en tant qu'agent dispersant et stabilisant.
DE19520659A1 (de) *	1995-06-09	1996-12-12	Mika Pharma Ges Fuer Die Entwi	Pharmazeutische Zubereitung zur Therapie und/oder Prophylaxe von durch Viren bedingten Erkrankungen der Haut und/oder der Schleimhaut
DE19719604A1 (de) *	1997-05-09	1998-07-16	Henkel Kgaa	Färbemittel für Keratinfasern

1999
- 1999-08-25 DE DE19940227A patent/DE19940227A1/de not_active Withdrawn
2000
- 2000-08-16 EP EP00960468A patent/EP1206245A2/de not_active Withdrawn
- 2000-08-16 CZ CZ2002561A patent/CZ2002561A3/cs unknown
- 2000-08-16 HU HU0203097A patent/HUP0203097A3/hu unknown
- 2000-08-16 JP JP2001518026A patent/JP2003507408A/ja active Pending
- 2000-08-16 SK SK244-2002A patent/SK2442002A3/sk unknown
- 2000-08-16 AU AU72767/00A patent/AU776766B2/en not_active Ceased
- 2000-08-16 PL PL00353215A patent/PL353215A1/xx not_active Application Discontinuation
- 2000-08-16 RU RU2002104972/15A patent/RU2261088C2/ru not_active IP Right Cessation
- 2000-08-16 WO PCT/EP2000/007993 patent/WO2001013887A2/de not_active Ceased
- 2000-08-16 CA CA002381571A patent/CA2381571A1/en not_active Abandoned
2002
- 2002-02-15 NO NO20020768A patent/NO20020768L/no not_active Application Discontinuation
- 2002-02-22 ZA ZA200201506A patent/ZA200201506B/xx unknown

Also Published As

Publication number	Publication date
DE19940227A1 (de)	2001-03-08
JP2003507408A (ja)	2003-02-25
RU2261088C2 (ru)	2005-09-27
CA2381571A1 (en)	2001-03-01
EP1206245A2 (de)	2002-05-22
ZA200201506B (en)	2003-05-28
WO2001013887A2 (de)	2001-03-01
WO2001013887A3 (de)	2001-09-20
NO20020768D0 (no)	2002-02-15
AU7276700A (en)	2001-03-19
HUP0203097A2 (hu)	2003-01-28
AU776766B2 (en)	2004-09-23
SK2442002A3 (en)	2002-08-06
PL353215A1 (en)	2003-11-03
NO20020768L (no)	2002-02-15
HUP0203097A3 (en)	2006-11-28

Publication	Publication Date	Title
AU2003303517B2 (en)	2007-10-25	Stable topical drug delivery compositions
CZ2002561A3 (cs)	2002-07-17	Fosfolipidový gel
US9050248B2 (en)	2015-06-09	Methods of delivering stable topical drug compositions
US8435942B2 (en)	2013-05-07	Methods for formulating stabilized insulin compositions
US20100311696A1 (en)	2010-12-09	Topical skin treatment composition
BRPI0512583B1 (pt)	2018-12-26	composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções
RU2006146921A (ru)	2008-11-20	Органо-гелевые препараты для терапевтического применения
US20170224639A1 (en)	2017-08-10	4-hydroxy tamoxifen gel formulations
KR101147672B1 (ko)	2012-05-21	경피 흡수 제제
TW201803561A (zh)	2018-02-01	軟性抗膽鹼類似物之製劑
RU2389483C2 (ru)	2010-05-20	Химически устойчивые композиции 4-гидрокси-тамоксифена
JP3924017B2 (ja)	2007-06-06	外用医薬組成物
ES2318563T3 (es)	2009-05-01	Formulaciones de gel de 4-hidroxi tamoxifeno.
BR112021003746A2 (pt)	2021-05-25	sistema de distribuição transdermal de fármacos
BR112021003746B1 (pt)	2023-09-12	Formulação para distribuição transdérmica de um ingrediente ativo a um mamífero, e kit
WO2002011679A1 (en)	2002-02-14	Compositions for topical applications and production thereof
HK1103027B (en)	2009-04-17	4-hydroxy tamoxifen gel formulations